Recently, TREM-1 expression was also first studied in a large series of 701 human breast cancers samples (35) (obtained before neoadjuvant chemotherapy), classified in three distinct immune groups (favorable/weak or poor immune dispositions (FID/WID or PID) respectively; based on immune gene signatures). Here, TREM1 is linked to breast carcinoma.